| Retirado antes de empezar | Fase 2/3 | Linvoseltamab · LINKER-MM8Mieloma multiple (MM) | may 2038 (prevista) |
| Retirado antes de empezar | no aplica | ENSEMBLEA Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations | jun 2030 (prevista) |
| Retirado antes de empezar | no aplica | aflibercept 8 mg · SPECTRUM-USAn Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting | ene 2028 (prevista) |
| Retirado antes de empezar | Fase 4 | dupilumab · BUILD-PEDSDermatitis atopica grave (AD) | dic 2027 (prevista) |
| Interrumpido | Fase 1/2 | REGN7041 · TITANA Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants | jul 2026 (real) |
| Completado | Fase 3 | mibavademabA Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) | jul 2026 (real) |
| Retirado antes de empezar | Fase 2 | cemiplimabCarcinoma escamoso cutaneo | jun 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Retirado antes de empezar | Fase 1 | GaretosmabObesidad | jun 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 2 | REGN7544 · PINNACLEStudy of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) | may 2026 (real) |
| Interrumpido | Fase 3 | REGN5713Conjuntivitis alergica | may 2026 (real) |
| Completado | Fase 1 | cemiplimab · CLIO-1A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies | abr 2026 (real) |
| Completado | no aplica | DUPIXENT® · RAPIDAsma | abr 2026 (real) |
| Completado | no aplica | dupilumabAn Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD) | abr 2026 (real) |
| Completado | Fase 2 | REGN9933 · ROXI-CATHA Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) | mar 2026 (real) |
| Completado | Fase 1 | ALN-APOC3ALN-APOC3 in Adult Participants With Dyslipidemia | feb 2026 (real) |
| Completado | Fase 2 | REGN7544 · ESTELLAA Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension | feb 2026 (real) |
| Completado | Fase 1 | REGN9533Voluntarios sanos | ene 2026 (real) |
| Completado | Fase 1 | CemiplimabIntralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma | nov 2025 (real) |
| Completado | no aplica | dupilumabPost-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy | nov 2025 (real) |
| Interrumpido | Fase 2 | REGN5381 · NATRIX-SBPREGN5381 in Adult Participants With Uncontrolled Hypertension | oct 2025 (real) |
| Interrumpido | Fase 1 | REGN5093-M114Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer | oct 2025 (real) |
| Completado | no aplica | cemiplimab · CASECemiplimAb Survivorship Epidemiology | sep 2025 (real) |
| Interrumpido | Fase 1 | bbT369A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | sep 2025 (real) |
| Interrumpido | Fase 2 | REGN5381 · NATRIX-BNPInsuficiencia cardiaca | sep 2025 (real) |
| Completado | no aplica | aflibercept 2mgIncidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study | ago 2025 (real) |
| Completado | Fase 1 | ELM-1Linfoma no Hodgkin · Leucemia linfocitica cronica | ago 2025 (real) |
| Completado | no aplica | aflibercept 2 mgA Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US) | ago 2025 (real) |
| Completado | Fase 1 | ALN-PNPA Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor | jul 2025 (real) |
| Completado | Fase 2 | REGN5381Insuficiencia cardiaca | jun 2025 (real) |
| Completado | Fase 3 | REGN1908Conjuntivitis alergica | may 2025 (real) |
| Completado | Fase 1/2 | REGN5459First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | may 2025 (real) |
| Completado | Fase 3 | REGN5713Conjuntivitis alergica | abr 2025 (real) |
| Completado | Fase 3 | PemetrexedStudy of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | abr 2025 (real) |
| Completado | Fase 1 | AspirinVoluntarios sanos | abr 2025 (real) |
| Completado | Fase 1 | REGN17092Voluntarios sanos | mar 2025 (real) |
| Completado | Fase 3 | REGN2810Cancer de pulmon no microcitico | feb 2025 (real) |
| Completado | Fase 1 | REGN13335Voluntarios sanos | feb 2025 (real) |
| Interrumpido | Fase 1 | REGN6569Carcinoma escamoso de cabeza y cuello | feb 2025 (real) |
| Completado | Fase 2 | REGN7508 · ROXI-VTE IIA Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants | nov 2024 (real) |
| Completado | Fase 4 | dupilumab · DISCOVERDupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial | nov 2024 (real) |
| Interrumpido | Fase 2 | vidutolimodA Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | oct 2024 (real) |
| Interrumpido | Fase 1 | REGN7257REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | oct 2024 (real) |
| Completado | Fase 1 | REGN7508Voluntarios sanos | sep 2024 (real) |
| Completado | no aplica | Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma | sep 2024 (real) |
| Interrumpido | Fase 2/3 | CMP-001CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | jul 2024 (real) |
| Completado | Fase 1 | REGN7544Voluntarios sanos | jul 2024 (real) |
| Completado | Fase 2/3 | dupilumab · LIBERTY-BPA Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | jul 2024 (real) |
| Completado | Fase 3 | aflibercept 8 mg PFSStudy to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) | may 2024 (real) |
| Completado | Sin fase asignada | T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge | may 2024 (real) |
| Completado | Fase 2 | REGN9933A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants | may 2024 (real) |
| Completado | Fase 1 | REGN9035Voluntarios sanos | abr 2024 (real) |
| Completado | Fase 1 | REGN3767Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | abr 2024 (real) |
| Interrumpido | Fase 2 | CMP-001CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | feb 2024 (real) |
| Interrumpido | Fase 2 | CMP-001Carcinoma escamoso de cabeza y cuello | ene 2024 (real) |
| Interrumpido | Fase 2 | REGN4461 · LEAPA Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) | dic 2023 (real) |
| Retirado antes de empezar | Fase 1 | REGN2810Tumores malignos avanzados | nov 2023 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 2 | cemiplimabStudy of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | oct 2023 (real) |
| Completado | no aplica | ORCHIDReal-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | oct 2023 (real) |
| Completado | no aplica | FLORAReal-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma | oct 2023 (real) |
| Completado | no aplica | A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP) | sep 2023 (real) |
| Completado | Fase 1 | REGN7999Voluntarios sanos | ago 2023 (real) |
| Completado | Fase 2 | REGN5713Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants | jul 2023 (real) |
| Completado | Fase 2 | dupilumabInvestigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) | jul 2023 (real) |
| Completado | Fase 4 | dupilumabAsma | jul 2023 (real) |
| Interrumpido | Fase 3 | Cemdisiran · ACCESS 2Hemoglobinuria paroxistica nocturna | jul 2023 (real) |
| Completado | Fase 1 | REGN14284Voluntarios sanos | may 2023 (real) |
| Completado | Fase 2 | CemiplimabCancer de cuello de utero | may 2023 (real) |
| Interrumpido | Fase 1/2 | cemiplimabREGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | may 2023 (real) |
| Completado | Fase 3 | evinacumabEvaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | abr 2023 (real) |
| Completado | Sin fase asignada | AspirinVoluntarios sanos | abr 2023 (real) |
| Completado | Fase 1 | REGN9933Voluntarios sanos | abr 2023 (real) |
| Completado | no aplica | dupilumabObservational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis | mar 2023 (real) |
| Interrumpido | Fase 1 | BPX-601Cancer de prostata metastasico resistente a la castracion | mar 2023 (real) |
| Completado | no aplica | dupilumab · NEURADADNeuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis | mar 2023 (real) |
| Interrumpido | Fase 2 | evinacumabHipertrigliceridemia | feb 2023 (real) |
| Completado | Fase 1 | REGN15160Voluntarios sanos | ene 2023 (real) |
| Interrumpido | Fase 3 | REGN1908-1909A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat | ene 2023 (real) |
| Completado | no aplica | A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022 | dic 2022 (real) |
| Retirado antes de empezar | Fase 2 | CemiplimabAnti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma | dic 2022 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 1 | REGN5381Voluntarios sanos | dic 2022 (real) |
| Completado | Fase 1 | CMP-001Melanoma | dic 2022 (real) |
| Completado | Fase 2 | casirivimab+imdevimabCOVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers | nov 2022 (real) |
| Interrumpido | Sin fase asignada | Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH) | oct 2022 (real) |
| Completado | Fase 2 | PozelimabHemoglobinuria paroxistica nocturna | oct 2022 (real) |
| Completado | Fase 3 | dupilumabA Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT) | ago 2022 (real) |
| Completado | Fase 3 | aflibercept · BUTTERFLEYEStudy to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity | ago 2022 (real) |
| Interrumpido | Fase 1/2 | REGN14256COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease | jun 2022 (real) |
| Completado | Fase 3 | DupilumabDermatitis atopica | jun 2022 (real) |
| Completado | Fase 1 | PozelimabVoluntarios sanos | jun 2022 (real) |
| Interrumpido | Fase 1 | casirivimab+imdevimabCOVID-19 | jun 2022 (real) |
| Completado | Fase 1 | Casirivimab+ImdevimabCOVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers | jun 2022 (real) |
| Completado | Fase 3 | Dupilumab · EoE KIDSStudy to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) | jun 2022 (real) |
| Interrumpido | Fase 2 | casirivimab+imdevimabCOVID-19 | jun 2022 (real) |
| Completado | Fase 2/3 | aflibercept · PHOTONEdema macular diabetico · Diabetes tipo 1 · Diabetes tipo 2 | may 2022 (real) |
| Interrumpido | Fase 3 | casirivimab+imdevimabA Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults | may 2022 (real) |
| Completado | Fase 2 | PozelimabHemoglobinuria paroxistica nocturna | may 2022 (real) |
| Interrumpido | Fase 3 | REGN3918Hemoglobinuria paroxistica nocturna | abr 2022 (real) |
| Retirado antes de empezar | Fase 3 | garetosmabStudy to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) | mar 2022 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 3 | EvinacumabEvaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia | ene 2022 (real) |
| Interrumpido | Fase 3 | casirivimab+imdevimab…COVID-19 | ene 2022 (real) |
| Completado | Fase 2 | Low-Dose REGN4461Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy | ene 2022 (real) |
| Completado | Fase 2 | CemiplimabCarcinoma escamoso cutaneo | dic 2021 (real) |
| Completado | Fase 1 | REGN10933+REGN10987Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19 | nov 2021 (real) |
| Completado | Fase 2/3 | PozelimabOpen-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) | nov 2021 (real) |
| Interrumpido | Fase 2 | SDREGN2810A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | oct 2021 (real) |
| Completado | Fase 3 | REGN10933 + REGN10987Voluntarios sanos | oct 2021 (real) |
| Completado | Fase 3 | DupilumabStudy to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) | sep 2021 (real) |
| Completado | Fase 3 | REGN5713Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis | ago 2021 (real) |
| Interrumpido | Fase 3 | REGN2810Cancer de pulmon no microcitico | jul 2021 (real) |
| Completado | Fase 1 | PozelimabVoluntarios sanos | jul 2021 (real) |
| Interrumpido | Fase 1 | 89Zr˗DFO˗REGN3504Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies | jul 2021 (real) |
| Completado | Fase 2/3 | Dupilumab · Liberty ADSafety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) | jul 2021 (real) |
| Completado | Fase 1 | CMP-001Melanoma maligno | jul 2021 (real) |
| Completado | Fase 2 | REGN3918Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | jun 2021 (real) |
| Interrumpido | Fase 1 | REGN6490Voluntarios sanos | jun 2021 (real) |
| Interrumpido | Fase 1 | REGN6490Voluntarios sanos | may 2021 (real) |
| Completado | Fase 2 | cemiplimabPD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy | may 2021 (real) |
| Completado | Fase 2 | aflibercept · CANDELASafety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | may 2021 (real) |
| Completado | Fase 1/2 | REGN10933+REGN10987 combination…COVID-19 | may 2021 (real) |
| Completado | Fase 3 | CemiplimabStudy of Cemiplimab in Adults With Cervical Cancer | mar 2021 (real) |
| Completado | Fase 1 | PozelimabVoluntarios sanos | mar 2021 (real) |
| Completado | Fase 2 | REGN10933+REGN10987 combination…COVID-19 | mar 2021 (real) |
| Completado | Fase 2 | DupilumabStudy to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy | feb 2021 (real) |
| Completado | Fase 3 | Fasinumab · FACT LTS & OALong-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip | dic 2020 (real) |
| Completado | Fase 2 | DupilumabStudy in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) | oct 2020 (real) |
| Interrumpido | no aplica | ALIROCUMAB SAR236553Hipercolesterolemia | sep 2020 (real) |
| Retirado antes de empezar | Fase 2 | REGN2477+REGN1033Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis | ago 2020 (prevista, ya pasada: sin actualizar en el registro) |
| Interrumpido | Fase 2 | FasinumabStudy to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip | ago 2020 (real) |
| Completado | Fase 4 | Intravitreal Aflibercept…Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe | ago 2020 (real) |
| Completado | Fase 2/3 | SarilumabCOVID-19 | jul 2020 (real) |
| Completado | Fase 2 | EvinacumabHipercolesterolemia | may 2020 (real) |
| Interrumpido | Fase 2 | REGN5069A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee | may 2020 (real) |
| Interrumpido | Fase 4 | PraluentLong Term Safety Study of PRALUENT | abr 2020 (real) |
| Completado | Fase 1 | REGN5713-5714-5715Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants | mar 2020 (real) |
| Interrumpido | Fase 2 | REGN3500Dermatitis atopica | mar 2020 (real) |
| Interrumpido | Fase 2 | REGN3500Dermatitis atopica | mar 2020 (real) |
| Completado | Fase 4 | PraluentHipercolesterolemia | mar 2020 (real) |
| Completado | Fase 2 | FasinumabStudy to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee | ene 2020 (real) |
| Completado | Fase 1 | REGN4461Voluntarios sanos | ene 2020 (real) |
| Completado | Fase 1 | Fasinumab AI · FACT DEVICETo Assess the Patients' Ability to Self-Administer Fasinumab | ene 2020 (real) |
| Completado | Fase 2 | REGN1908-1909Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge | dic 2019 (real) |
| Completado | Fase 2 | evinacumabSafety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis | dic 2019 (real) |
| Completado | Fase 3 | Fasinumab · FACT OA2Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip | dic 2019 (real) |
| Completado | Fase 1 | CMP-001Cancer de pulmon no microcitico | dic 2019 (real) |
| Interrumpido | Fase 1 | REGN4659Cancer de pulmon no microcitico | dic 2019 (real) |
| Completado | Fase 1 | CemiplimabCancer avanzado · Tumores malignos avanzados | nov 2019 (real) |
| Completado | Fase 1 | REGN5069Voluntarios sanos | sep 2019 (real) |
| Completado | Fase 3 | Alirocumab · ODYSSEY HoFHStudy in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | sep 2019 (real) |
| Completado | Fase 2 | REGN2477 · LUMINA-1A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva | sep 2019 (real) |
| Completado | Fase 3 | Fasinumab · FACT OA1A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip | sep 2019 (real) |
| Completado | Fase 1 | REGN2810An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) | jun 2019 (real) |
| Completado | Fase 3 | DupilumabStudy to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) | jun 2019 (real) |
| Completado | Fase 3 | evinacumabEfficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | jun 2019 (real) |
| Completado | Fase 2 | DupilumabDupilumab As An Adjunct For Subcutaneous Grass Immunotherapy | may 2019 (real) |
| Completado | Fase 1 | REGN1033Voluntarios sanos | abr 2019 (real) |
| Completado | Fase 1 | REGN3500Study of REGN3500 and Dupilumab in Patients With Asthma | mar 2019 (real) |
| Completado | Fase 1 | REGN2810Melanoma | mar 2019 (real) |
| Completado | Fase 1 | REGN3918Voluntarios sanos | ago 2018 (real) |
| Completado | Fase 1 | REGN3500Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma | ago 2018 (real) |
| Completado | Fase 3 | PANORAMAStudy of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) | ago 2018 (real) |
| Completado | Fase 1 | EvinacumabVoluntarios sanos | jun 2018 (real) |
| Interrumpido | Fase 3 | Fasinumab · FACT CLBP 1Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | may 2018 (real) |
| Completado | Fase 3 | DupilumabEfficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis | abr 2018 (real) |
| Completado | Fase 1 | DupilumabStudy of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis | nov 2017 (real) |
| Completado | Fase 2 | REGN910-3 · ONYXDegeneracion macular asociada a la edad neovascular | oct 2017 (real) |
| Completado | Fase 2 | REGN910-3 · RUBYEdema macular diabetico | jul 2017 (real) |
| Completado | Fase 3 | Suptavumab 30 mgInfeccion por virus respiratorio sincitial | jul 2017 (real) |
| Completado | Fase 1 | REGN3500Voluntarios sanos | jun 2017 (real) |
| Completado | Fase 1 | REGN3470-3471-3479Voluntarios sanos | abr 2017 (real) |
| Completado | Fase 2 | DupilumabStudy of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE) | feb 2017 (real) |
| Completado | Fase 2/3 | FasinumabA Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain | feb 2017 (real) |
| Completado | Fase 1 | REGN2477Voluntarios sanos | ene 2017 (real) |
| Completado | Fase 3 | DupilumabDermatitis atopica | ene 2017 (real) |
| Completado | Fase 2 | AlirocumabOpen-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) | dic 2016 (real) |
| Completado | Fase 2 | REGN1500 250 mg SCStudy of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | nov 2016 (real) |
| Completado | Fase 1 | REGN2222Voluntarios sanos | sep 2016 (real) |
| Interrumpido | Fase 2 | REGN2176-3 · CAPELLADegeneracion macular asociada a la edad neovascular | ago 2016 (real) |
| Completado | Fase 1 | DupilumabDermatitis atopica | jul 2016 (real) |
| Completado | Fase 3 | Dupilumab · SOLO-CONTINUEDermatitis atopica | jul 2016 (real) |
| Completado | Fase 1 | REGN1033Voluntarios sanos | abr 2016 (real) |
| Completado | Fase 2 | DupilumabDermatitis atopica | mar 2016 (real) |
| Completado | Fase 2/3 | REGN475Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip | mar 2016 (real) |
| Completado | Fase 1 | FasinumabVoluntarios sanos | feb 2016 (real) |
| Completado | Fase 3 | Alirocumab · ODYSSEY ESCAPEStudy of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy | ene 2016 (real) |
| Completado | Fase 1 | REGN1500Hipertrigliceridemia | ene 2016 (real) |
| Completado | Fase 1 | REGN1908-1909Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants | dic 2015 (real) |
| Interrumpido | Fase 1 | REGN1193Diabetes tipo 2 | dic 2015 (real) |
| Completado | Fase 3 | Dupilumab · SOLO 1Dermatitis atopica | nov 2015 (real) |
| Completado | Fase 3 | Dupilumab · SOLO 2Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | oct 2015 (real) |
| Completado | Fase 1 | REGN910-3Degeneracion macular asociada a la edad neovascular · Edema macular diabetico | oct 2015 (real) |
| Completado | Fase 2 | DupilumabDermatitis atopica | sep 2015 (real) |
| Completado | Fase 1 | REGN1500Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500 | sep 2015 (real) |
| Completado | Fase 4 | RE-VIEWStudy to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) | sep 2015 (real) |
| Completado | Fase 3 | Dupilumab · CHRONOSDermatitis atopica | ago 2015 (real) |
| Completado | Fase 1 | SarilumabArtritis reumatoide | abr 2015 (real) |
| Completado | Fase 1 | REGN2222Voluntarios sanos | feb 2015 (real) |
| Completado | Fase 1 | REGN1193Voluntarios sanos | ene 2015 (real) |
| Completado | Fase 2 | REGN1033Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia | ene 2015 (real) |
| Completado | Fase 1 | REGN1400Cancer | ene 2015 (real) |
| Completado | Fase 2 | DupilumabStudy to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) | dic 2014 (real) |
| Completado | Fase 1 | REGN2176-3Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD | dic 2014 (real) |
| Completado | Fase 1 | nesvacumabTumor solido | nov 2014 (real) |
| Completado | Fase 1 | REGN2009Voluntarios sanos | sep 2014 (real) |
| Completado | Fase 1 | nesvacumabTumor solido | sep 2014 (real) |
| Completado | Fase 3 | AlirocumabHipercolesterolemia | sep 2014 (real) |
| Completado | Fase 2 | AlirocumabHipercolesterolemia | jun 2014 (real) |
| Completado | Fase 1 | REGN1033Voluntarios sanos | jun 2014 (real) |
| Completado | Fase 3 | AtorvastatinHipercolesterolemia | may 2014 (real) |
| Completado | Fase 1 | REGN1908-1909Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects | may 2014 (real) |
| Completado | Fase 3 | LMT · ODYSSEY FH IIStudy of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) | may 2014 (real) |
| Completado | Fase 2 | DupilumabDermatitis atopica | may 2014 (real) |
| Completado | Fase 3 | AlirocumabHipercolesterolemia | abr 2014 (real) |
| Completado | Fase 3 | AlirocumabHipercolesterolemia | abr 2014 (real) |
| Completado | Fase 1 | REGN421A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies | feb 2014 (real) |
| Completado | Fase 3 | VIBRANTStudy to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO) | ago 2013 (real) |
| Completado | Fase 3 | Intravitreal Aflibercept…Degeneracion macular asociada a la edad neovascular | ago 2013 (real) |
| Interrumpido | Fase 3 | Rilonacept · UPSURGEGota | jun 2013 (real) |
| Completado | Fase 1 | REGN1033Voluntarios sanos | jun 2013 (real) |
| Interrumpido | Fase 1/2 | REGN846Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis | abr 2013 (real) |
| Completado | Fase 2 | DupilumabDermatitis atopica | mar 2013 (real) |
| Completado | Fase 3 | VISTA DMEEdema macular diabetico | ene 2013 (real) |
| Completado | Fase 1 | REGN1154 or placeboVoluntarios sanos | ene 2013 (real) |
| Completado | Fase 2 | DupilumabDermatitis atopica | dic 2012 (real) |
| Completado | Fase 1 | REGN1033Voluntarios sanos | nov 2012 (real) |
| Completado | Fase 4 | ColchicineEfficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol | ago 2012 (real) |
| Completado | Fase 1 | REGN668Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis | jul 2012 (real) |
| Completado | Fase 1 | DupilumabDermatitis atopica | mar 2012 (real) |
| Completado | Fase 1 | REGN728Voluntarios sanos | mar 2012 (real) |
| Completado | Fase 1 | REGN668: Injection Rate 1Voluntarios sanos | feb 2012 (real) |
| Completado | Fase 2 | AlirocumabHipercolesterolemia | nov 2011 (real) |
| Completado | Fase 2 | VEGF Trap EyeRandomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD | oct 2011 (real) |
| Completado | Fase 1 | REGN846Voluntarios sanos | sep 2011 (real) |
| Interrumpido | Fase 1/2 | AfliberceptA Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma | jun 2011 (real) |
| Completado | Fase 1 | REGN727Hipercolesterolemia | may 2011 (real) |
| Completado | Fase 3 | RilonaceptGota | ene 2011 (real) |
| Interrumpido | Fase 2 | REGN475Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain | ene 2011 (real) |
| Interrumpido | Fase 2 | REGN475Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain | ene 2011 (real) |
| Completado | no aplica | A Study of Tocilizumab in Patients With Rheumatoid ArthritisArtritis reumatoide | dic 2010 (real) |
| Completado | Fase 3 | RilonaceptGota | dic 2010 (real) |
| Completado | Fase 1 | REGN727Voluntarios sanos | nov 2010 (real) |
| Completado | Fase 3 | VEGF Trap-Eye 2.0mgVascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) | oct 2010 (real) |
| Completado | Fase 1 | REGN727Voluntarios sanos | oct 2010 (real) |
| Completado | Fase 3 | ranibizumab · VIEW1Degeneracion macular | sep 2010 (real) |
| Completado | Fase 1 | REGN668Voluntarios sanos | jul 2010 (real) |
| Completado | Fase 2 | REGN475A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain | may 2010 (real) |
| Completado | Fase 1/2 | REGN475A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee | may 2010 (real) |
| Completado | Fase 3 | Rilonacept 80 mg · PRE-SURGE1PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1 | may 2010 (real) |
| Completado | Fase 3 | Rilonacept · SURGEStudy Utilizing Rilonacept in Gout Exacerbations | feb 2010 (real) |
| Completado | Fase 2 | DA VINCIEdema macular diabetico | dic 2009 (real) |
| Completado | Fase 1 | REGN475Voluntarios sanos | nov 2009 (real) |
| Completado | Fase 1 | REGN88Artritis reumatoide | ago 2009 (real) |
| Completado | Fase 1 | REGN88Artritis reumatoide | mar 2009 (real) |
| Completado | Fase 1 | REGN88Artritis reumatoide | mar 2009 (real) |
| Completado | Fase 2 | RilonaceptGota | oct 2008 (real) |
| Completado | Fase 1 | rilonaceptStudy to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) | jun 2008 (real) |
| Completado | Fase 1 | VEGF TrapSafety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD | jun 2008 (real) |
| Completado | Fase 2 | aflibercept injectionSafety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD) | jun 2008 (real) |
| Completado | Fase 3 | rilonacept 160 mgRilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) | jun 2008 (real) |
| Completado | Fase 1 | ziv-afliberceptCancer | may 2008 (real) |
| Completado | Fase 1 | ziv-afliberceptCancer | may 2008 (real) |
| Completado | Fase 1 | VEGF TrapSafety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD | sep 2007 (real) |
| Completado | Fase 1 | ziv-afliberceptVEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma | feb 2007 (real) |
| Completado | Fase 1 | VEGF Trap-EyeEdema macular diabetico | ago 2006 (real) |
| Completado | Fase 1 | ziv-afliberceptVEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma | mar 2002 (real) |
| Ya no disponible | no aplica | REGN10933+REGN10987 combination…COVID-19 | sin fecha |
| Retirado antes de empezar | Fase 2 | R475Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury | sin fecha |
| Aprobado para comercializar | no aplica | CemiplimabCáncer de pulmón no microcítico (NSCLC) · Carcinoma basocelular (BCC) · Carcinoma escamoso cutáneo (CSCC) | sin fecha |
| Aprobado para comercializar | no aplica | EvinacumabCompassionate Use of Evinacumab | sin fecha |
| Ya no disponible | no aplica | cemiplimabCarcinoma escamoso cutaneo | sin fecha |
| Aprobado para comercializar | no aplica | REGN5458Mieloma multiple | sin fecha |
| Ya no disponible | no aplica | PozelimabHemoglobinuria paroxistica nocturna | sin fecha |
| Ya no disponible | no aplica | VidutolimodCompassionate Use of Vidutolimod | sin fecha |
| Aprobado para comercializar | no aplica | PozelimabCompassionate Use of Pozelimab | sin fecha |
| Retirado antes de empezar | Fase 2 | REGN475Artrosis | sin fecha |
| No disponible temporalmente | no aplica | GaretosmabAn Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) | sin fecha |
| Retirado antes de empezar | Fase 2 | RilonaceptEnfermedad renal cronica · Anemia | sin fecha |
| Aprobado para comercializar | no aplica | Pozelimab · CHAPLE DiseaseCompassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy | sin fecha |
| Aprobado para comercializar | no aplica | dupilumabCompassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid | sin fecha |